TIDMMTPH

RNS Number : 7227K

Midatech Pharma PLC

06 September 2021

6 September 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Notice of Interim Results

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021.

The Company will be hosting a webinar at 5.30pm BST / 12.30pm EST on Monday 20 September 2021. The webinar is open to all existing and potential shareholders and those interested in attending may register via the following link where, following registration, they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_vLpYaALlRYqUXveBsffy7w

Participants may submit questions during the webinar or in advance via email to: midatech@investor-focus.co.uk

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)29 2048 0180 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 Tel: +44 (0)20 7886 2500 
 
 Turner Pope Investments (TPI) Limited (Joint Broker) 
 Andrew Thacker / James Pope (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Maxwell Colbert 
  Tel: +1 (646) 653 7028 
  Email: mcolbert@edisongroup.com 
           About Midatech Pharma PLC 
            Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
            MTP) is a drug delivery technology company focused on improving 
            the bio-delivery and bio-distribution of medicines. The Company 
            combines approved and development medications with its proprietary 
            and innovative drug delivery technologies to provide compelling 
            products that have the potential to powerfully impact the 
            lives of patients. 
            The Company has developed three in-house technology platforms, 
            each with its own unique mechanism to improve delivery of 
            medications to sites of disease. All of the Company's technologies 
            have successfully entered human use in the clinic, providing 
            important validation of the potential for each platform: 
             *    Q-Sphera(TM) platform: a disruptive micro-technology 
                  used for sustained release to prolong and control the 
                  release of therapeutics over an extended period of 
                  time (from weeks to months). 
 
 
             *    MidaSolve(TM) platform: an innovative nanotechnology 
                  used to dissolve insoluble drugs so that they can be 
                  administered in liquid form directly and locally into 
                  tumours. 
 
 
             *    MidaCore(TM) platform: a leading-edge nanotechnology 
                  used for targeting medications to sites of disease. 
 
 
 
            The platform nature of the technologies offers the potential 
            to develop multiple drug assets rather than being reliant 
            on a limited number of programmes. Midatech's technologies 
            are supported by 36 patent families including 120 granted 
            patents and an additional 70 patent applications. Midatech's 
            headquarters and R&D facility is in Cardiff, UK. For more 
            information please visit www.midatechpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFLFLFADIVIIL

(END) Dow Jones Newswires

September 06, 2021 02:00 ET (06:00 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.